CCXI - Healthcare names dominate premarket gainers
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24% after confirming receipt of unsolicited proposal.Chemomab Therapeutics (CMMB) +26%.Graybug Vision (GRAY) +25%.ChemoCentryx (CCXI) +14%.Senseonics Holdings (SENS) +14%.Atotech Limited (ATC) +8% as MKS Instruments approaches Atotech with acquisition offer.Aptinyx (APTX) +7%.Equillium (EQ) +7% on positive topline results from the EQUATE Study.Vinco Ventures(BBIG) +7%.Adamis Pharmaceuticals Corporation (ADMP) +7% after update on clinical trial start-up progress for Tempol.Recon Technology, Ltd. (RCON) +7%.Aytu Biopharma (AYTU) +6%.Lucira Health (LHDX) +5%.iBio (IBIO) +6%.UWM Holdings Corporation Class (UWMC) +6%.Mustang Bio (MBIO) +7% on updated interim Phase 1/2 data for MB-106.Virios Therapeutics (VIRI) +6%.Eton Pharmaceuticals, Inc. (ETON) +6%.CRISPR Therapeutics AG (CRSP) +6% after new CTX001 data in beta thalassemia and sickle cell disease.Evofem Biosciences, Inc. (EVFM) +5%.
For further details see:
Healthcare names dominate premarket gainers